collaborators

6 papers

stat.ME2026

Communicating results in trials with multiple hypotheses or adaptive design features

Elina Asikanius, Marcel Wolbers, Mouna Akacha +8

Over time, clinical trials have increasingly incorporated complex design and analysis elements such as interim analyses, adaptations, multiple endpoints, and sophisticated multipli…

stat.ME2026

Navigating the Landscape of Hierarchical Multi-Component Strategies: GPC, DOOR, and MOST

Mickaël De Backer, Johan Verbeeck, Vivian Lanius +5

There is a growing recognition of the importance to involve patients in every stage of drug development. This shift acknowledges that patients' perspectives, experiences, and prefe…

stat.ME2026

Clustering-Based Outcome Models for Clinical Studies: A Scoping Review

Johannes Vilsmeier, Fabian Eibensteiner, Franz König +6

This review provides a systematic overview of methods that combine covariate-based clustering of observational units (patients) with outcome models for clinical studies. We disting…

stat.OT2026

Statistical Methodology Groups in the Pharmaceutical Industry

Jenny Devenport, Tobias Mielke, Mouna Akacha +10

Research and Development is the largest budget position in the pharmaceutical industry, with clinical trials being a critical, yet costly and time-consuming component to inform dec…

q-bio.QM2025

In silico clinical trials in drug development: a systematic review

Bohua Chen, Lucia Chantal Schneider, Christian Röver +15

In the context of clinical research, computational models have received increasing attention over the past decades. In this systematic review, we aimed to provide an overview of th…

stat.AP2025

WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors

Konstantinos Sechidis, Sophie Sun, Yao Chen +8

This paper proposes a Workflow for Assessing Treatment effeCt Heterogeneity (WATCH) in clinical drug development targeted at clinical trial sponsors. WATCH is designed to address t…